Making the most of rodent tumour systems in cancer drug discovery by Bibby, M C
It is clear that even after almost half a century of intensive effort to
develop effective treatments for common solid cancers there is
still some way to go before a major impact on survival of patients
with these malignancies is achieved. Much of the paucity of
success is blamed on the lack of appropriate models and there is a
commonly held belief amongst cancer researchers that trans-
plantable tumours in rodents are sensitive to drug therapy, are easy
to cure and therefore not predictive of responses in humans. It is
true that, in the past, when one considers the large number of
compounds evaluated, murine tumour models have identified only
a limited number of clinically useful agents and not a single
cancer-specific drug has resulted from a murine tumour screen. It
is easy with hindsight to blame this disappointing lack of really
effective therapies on inappropriate test systems and screening
strategies but, although drug discovery from rodent systems has
been sparse, in reality, an enormous contribution to cancer therapy
principles has emanated from such studies. This work really began
in the mid 1950s when the National Cancer Institute (NCI) in the
USA initiated a large-scale anti-cancer drug-screening programme
using three murine tumour models: sarcoma 180, L1210
leukaemia and carcinoma 755 (Plowman et al, 1997). Of major
significance in the early days was the work of Skipper and
colleagues who, by the use of experimental leukaemia models,
established the principle of survival/inoculum relationship
(Skipper et al, 1957) and also the concept of fractional cell kill, i.e.
that the percentage of the tumour cell population killed by a given
dose of drug was relatively constant (Skipper et al, 1964). They
also described a close relationship between dose level and
percentage of leukaemic cell population killed, i.e. a
dose–response relationship. Other useful therapeutic strategies
were first established in rodent systems. The principle of optimum
scheduling was first described by Goldin et al (1956) using the
L1210 leukaemia. Combination chemotherapy and the concept of
therapeutic synergism was first investigated in rodent models
(Goldin and Mantel, 1957) as was combining the modalities of
surgery and chemotherapy – adjuvant chemotherapy (Martin,
1981).
Many of the early experimental studies utilized murine
leukaemias which grew very rapidly, had a high growth fraction
and proved to be sensitive to a number of agents that were subse-
quently shown to have more activity against leukaemias and
lymphomas than against solid carcinomas or sarcomas and to be
toxic to the bone marrow (Muggia, 1987). A number of investiga-
tors believed that the use of more appropriate, slower growing
tumour models of solid cancers, and adoption of clinically relevant
end-points, would improve the usefulness of preclinical studies,
particularly for agents with potential activity against the common
solid cancers. Corbett et al (1987) pointed out that most of the
agents that had entered the clinic at that time had poor, or no,
activity against the majority of transplantable solid tumours in
mice but they also suggested that, as negative findings are rarely
reported, the casual reader of the drug discovery literature may
have gained the inaccurate impression that transplantable tumours
in mice are highly vulnerable to a large proportion of agents that
make the clinic.
THERAPEUTIC INDEX
The importance of addressing the therapeutic index of investiga-
tional agents has been stressed by many groups over the years,
including our own (Double and Bibby, 1989) and we have advo-
cated a more thorough preclinical evaluation of new cytotoxic
entities which assesses efficacy and normal tissue toxicity in the
same setting (Bibby et al, 1988). Taking mitozolomide (Stevens
et al, 1984) as an example compound that had recently entered
clinical trial, we evaluated anti-tumour activity in a limited panel
of refractory murine tumours but we also investigated normal
tissue toxicity at the active doses. Mitozolomide showed a poor
therapeutic ratio in this test system with modest anti-tumour
effects being seen close to maximum tolerated dose (MTD) only.
At this dose level there was very severe normal tissue toxicity in
mice (Table 1). Mitozolomide is an example of (at that time) a
novel chemical that showed exciting pre-clinical activity in some
experimental tumour systems with cures in L1210 and P388 at half
the LD10 but went on to behave poorly in the clinic due to unman-
ageable haematological toxicity. Although rodent studies do not
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Table 1 Bone marrow toxicity of mitozolomide assessed by spleen colony
forming unit (CFU-S) assay in mice
Donor Recipient
Dose Radiation No. of bone marrow cells CFU-S
(mg kg-1) (Gy) injected
– 11.7 1.2 ´ 104 40
20 11.7 1.0 ´ 105 4
30 11.7 9.0 ´ 104 3
40 11.7 1.0 ´ 105 0
n = 6 mice per group. Data taken from Bibby et al 1988.necessarily predict human organ toxicity, they do appear to be
helpful in predicting effects in some organs, e.g. bone marrow.
Hindsight has shown that mitozolomide was selected for clinical
trial on the basis of results from inappropriate pre-clinical models
that did not reflect the resistance of clinical disease, but the group
has gone on to develop a useful less toxic analogue,
Temozolomide (Newlands et al, 1997).
THERAPEUTIC END-POINTS
In the early 1980s, Martin and colleagues discussed the signifi-
cance of the methodology used in recording response (Martin et al,
1984). They assessed the importance of selecting an appropriate
end-point in preclinical studies by comparing response rates in
breast cancer patients to six agents and then evaluating the same
six agents in a murine model of spontaneous breast cancer, the
CD8F1 (Stolfi et al, 1988). The breast cancer patients responded
only to melphalan, cyclophosphamide and 5-fluorouracil (5-FU).
When the authors evaluated response in the murine system by
percentage tumour inhibition, all six agents could be classified as
active, whereas when they employed tumour regression as a
measure of activity, as in the patients, only the three clinically
active agents were effective (Table 2). Despite these observations
cytotoxic agents have still progressed to clinical study on the basis
of tumour growth delay in rodents at MTD and have often been
shown to be ineffective in humans at doses that can be tolerated.
Obviously there are certain ethical considerations that need to
be addressed when selecting model systems and end-points for in
vivo studies. As long as appropriate guidelines for animal welfare
are followed (e.g. UKCCCR; Workman et al, 1998), subcutaneous
models of neoplasia are relatively straightforward to use and
potential animal suffering can be monitored and appropriate
humane end-points, such as tumour size, utilized. However, the
use of ascites tumour models and survival end-points to investi-
gate the activity of intraperitoneally administered agents is diffi-
cult to justify on scientific or ethical grounds. These should not be
used for preclinical screening as they can result in undue suffering
and provide little more information than well-designed in vitro
assays. Lethality end-points should be avoided in general, even for
models of systemic disease, and histological and/or metastatic
colony counting techniques should be employed to assess anti-
tumour effects. As modern therapeutic strategies develop, more
effort is required to ensure suitable pharmacodynamic end-points
are in place to assess whether or not a designed therapy is
achieving its goal in vivo.
IN VITRO CELL LINE PANELS
As a result of expanding knowledge, but also limited success, in
the identification and development of drugs with useful activity in
common solid cancers, drug-screening programmes in the NCI
and elsewhere have evolved considerably over the years
(Plowman et al, 1997) until in 1985 the NCI began to assess the
feasibility of using human tumour cell lines for large-scale
compound screening (Boyd, 1989). It is beyond the scope of this
article to extol the virtues or otherwise of this approach to drug
discovery but it is clear that, as a result of its inception, many inter-
esting molecules are continually emerging and these will require
appropriate in vivo evaluation. The NCI cell line panel has
expanded since it was initially set up and there is ongoing develop-
ment and characterization of potential new molecular targets.
Although the initial strategy for the cell line screen was to develop
a disease-orientated approach, the addition of the molecular char-
acterization of the cell line panel opens up the possibility for
target-orientated screening. The option to use genetically modified
cell lines to address specific molecular targets at the in vitro stage
is now available. This scientifically sound strategy of target-orien-
tated drug development must be extended into in vivo evaluation
protocols, so not only should in vivo studies be carried out in
tumours derived from cell lines that were identified as sensitive in
vitro, but it is imperative that adequate characterization of these
models demonstrates that the molecular characteristics of the cell
line are retained in the in vivo setting.
PHARMACOKINETIC CONSIDERATIONS
Going from cell-free screening strategies and cell lines to in vivo
studies represents a major step in the drug-discovery pathway and
one very important requirement is knowledge of the pharmaco-
kinetics of investigational agents at an early stage. Ideally, such
studies should be carried out alongside efficacy investigations
with a view to either selecting those agents with the best pharma-
ceutical properties or, alternatively, formulating or even modifying
the active component to optimize the therapeutic effect.
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Table 2 Importance of clinically relevant endpoints in predictability of preclinical anti-tumour studies
Drug Human CD8F1 spontaneous
breast cancer breast tumours
Inhibited (%)a Assessment Regression Assessmentb
Melphalan + 88 + 7/24 +
Cyclo + 80 + 5/25 +
FU + 79 + 13/60 +
N-phosphon-acetylaspartate – 63 + 2/47 –
Ara-c – 33 + 1/37 –
6-thioguanine – 52 + 0/45 –
aStatistically significant; bat least 50% reduction. Data taken from Stolfi et al 1988.HOLLOW-FIBRE ASSAYS
One relatively new approach to in vivo drug testing has been
developed at NCI utilizing human cell-lines growing in hollow
fibres. It is intended as a method for prioritizing compounds for
testing in xenografts. At present, 10 000 compounds are screened
in vitro against the cell line panel each year by NCI and 8–10% are
referred for in vivo testing (Plowman et al, 1997). For the hollow-
fibre assay, tumour cells are inoculated into 1-mm internal
diameter hollow-fibres that are heat-sealed and cut into 2 cm
lengths. The fibres are maintained in in vitro culture for 24–48 h
and then implanted intraperitoneally and subcutaneously into nude
mice. Three different cell lines can be grown in two different sites
in the same mouse. The effects of treatment are determined by
MTT assay on removal of the fibres 6–8 days post-implantation.
On the face of it, this technique would seem an efficient way
of identifying lead compounds of promise because it requires
relatively small expenditure and a limited quantity of test
compound. Of course, as mentioned earlier, it cannot be assumed
that expression of a particular target will be identical in vivo to that
expressed when the same cells are grown in vitro or vice versa.
TUMOUR CHARACTERIZATION
For several years our laboratory has been involved in studies of
potential bioreductive drugs but in particular we have developed
an interest in the role of the dimeric flavoprotein DT-diaphorase
(DTD, NAD(P)H:Quinone acceptor reductase, E.C.1.6.99.2) in the
activation of a number of quinone based anti-cancer drugs
(Phillips, 1996). There is a wealth of literature indicating a good
correlation between enzyme activity in cell lines and aerobic
chemosensitivity to compounds like EO9, 3-hydroxy-5-aziridinyl-
1-methyl-2(1H-indole-4,7-dione)-prop-b-en-a-o1 (Robertson et
al, 1992; Smitskamp-Wilms et al, 1994; Collard et al, 1995;
Fitzsimmons et al, 1996). However, when attempts were made to
translate these in vitro observations into in vivo studies it became
apparent that DTD activity in human tumour xenografts derived
from cell lines did not usually mirror levels seen in vitro (Collard
et al, 1995), indicating the necessity to further characterize
xenografts for the appropriate target for which therapeutic mole-
cules are being sought. In the case of DTD, antibodies are
available (Segura-Aguilar et al, 1994) so it is possible to identify
the precise location of the protein within tissue sections (Segura-
Aguilar et al, 1994; Phillips et al, 1998), and similar immunolocal-
ization can be carried out now with a whole host of target enzymes
and other molecular targets. It is certain that the majority of targets
currently being investigated for drug development strategies will
be influenced by their local environment, so not only will there be
differential target expression in different tumours but there will
also be different expression in vivo from that seen in in vitro
culture of the same tumour cells. Furthermore, it is clear that
tumour site within the body can influence the expression of
specific targets, e.g. P-glycoprotein. Fidler and colleagues investi-
gated response to doxorubicin (DOX) or 5-FU in three tumour
types growing in different anatomical sites (Dong et al, 1994;
Fidler et al, 1994). Sensitivity to 5-FU did not alter with anatom-
ical site but lung and tumour deposits were resistant to DOX
whereas subcutaneous (s.c.) tumours were sensitive. The authors
determined that the difference in response was not due to
differences in DOX distribution or potency but resulted from
over expression of mdr1 mRNA in the resistant sites, they made
the valid point that human colon cancer xenografts growing sub-
cutaneously in nude mice often respond to DOX, whereas human
colon cancer does not. These observations reiterate the require-
ment for continual target characterization in in vivo models. Since
modern molecular biology allows for the dissection of signalling
pathways instrumental in cell proliferation and death, the number
of potential molecular targets for drug development is increasing.
Preclinical systems must be selected or designed in such a way to
ensure that the appropriate target is expressed, and the appropriate
controls in which the target is down-regulated or missing should
be used in order to establish proof of principle and to ensure the
validity of the therapeutic mechanism.
HOST EFFECTS
Although a molecular target approach using high-throughput,
robotic cell-free in vitro screens or cell line panels followed by
properly characterized in vivo models should increase the effi-
ciency of drug-discovery programmes, novel therapeutic strategies
for cancer are clearly not going to be identified only by in vitro
screening. These screens do not take into consideration indirect
mechanisms such as host metabolism to an active species or
immunomodulation. Within the rapidly expanding field of tumour
biology several new therapeutic avenues are being explored that
address host/tumour relationships or exploit specific features of
solid tumours, thus relying even more on clinically relevant
preclinical in vivo models.
TUMOUR BLOOD SUPPLY
One area of solid tumour biology that has been receiving a great
deal of attention over recent years is the tumour blood supply.
Broadly speaking, to date there are four different strategies
attempting to exploit the tumour blood supply for therapeutic gain
and all rely not only on differences in the architecture and cellular,
biochemical and molecular properties between normal and tumour
vasculature but also on the use of a properly characterized model.
The major thrust at present seems to be concerned with anti-angio-
genesis, i.e. a strategy to prevent the development of new blood
vessels and to restrict solid tumour growth. There has been an
enormous leap in our understanding of the processes and molec-
ular control of tumour angiogenesis in recent years and the anti-
angiogenic approach has been the subject of some excellent
comment articles and reviews (Folkman, 1990, 1997; Baillie et al,
1995; Pluda, 1997). Modulation of tumour growth by the use of
monoclonal antibodies to vascular endothelial growth factor
(VEGF) has proved successful in preclinical studies (Warren et al,
1995) but the rational design of drugs which will specifically inter-
fere with steps in the angiogenic process in tumours is in its
infancy as is the development of gene therapy approaches (Kong
and Crystal, 1998). However, targets are being identified, so
continual development, improvement and characterization of in
vivo tumour models in which to test specific strategies is required.
The other attempts to exploit tumour blood supply have concen-
trated on the existing blood vessels within solid tumours. One
approach relies on the lack of smooth muscle and innervation of
the new blood vessels growing in solid tumours. Several experi-
mental studies have demonstrated potentiation of the activity of
both standard and investigational drugs by combination with a
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flow in tumour models (Hirst and Wood, 1989) but many experi-
mental studies utilized the anti-hypertensive hydralazine which
has been shown to decrease blood flow through transplantable
tumours in rodents (Chan et al, 1984; Jirtle, 1988). Hydralazine
enhanced the effectiveness of bioreductive drugs, such as the
nitroimidazole RSU 1069 (Chaplin and Acker, 1987), tirapaza-
mine (Brown, 1987), EO9 (Bibby et al, 1993) and mitomycin C
(Cowen et al, 1994) but potentiation was also seen with melphalan
(Stratford et al, 1988) and tauromustine (Quinn et al, 1992).
Although these and other similar studies indicated a potential ther-
apeutic strategy they have not yet resulted in a clinical advantage.
Rowell et al (1990) showed that single-dose oral hydralazine
caused the blood flow through human lung tumours to decrease
rather than increase. A study by Field et al (1991) demonstrated a
difference in the effects of hydralazine on vascular perfusion
between a series of primary and subcutaneously transplanted
malignancies. The transplanted tumours responded to hydralazine
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Figure 1 Diagramatic representation of Enhanced Permeability and Retention in tumours (Matsumura and Maeda, 1986)
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Figure 2 Chemical structure of PK1 (Duncan, 1992)whereas the primary tumour from which they were derived did not.
Only 4/11 primary tumours responded to hydralazine. All the
tumours used in the preceding papers were transplanted subcuta-
neously in mice so, although they may have established proof of a
particular hypothesis, the studies are unlikely to be clinically
predictive. An investigation from this laboratory (Cowen et al,
1995) demonstrated that hydralazine was more effective at shut-
ting down blood supply to s.c. murine colon tumours than to the
same tumours transplanted orthotopically, and the same dose of
hydralazine was completely ineffective in liver metastasis in this
model. These studies highlight the lack of prediction by s.c.
tumours for this strategy and the importance of selecting clinically
relevant tumour models in appropriate anatomical sites.
Another approach to targeting solid tumours by means of their
poorly formed blood vessels relies on the enhanced permeability
and retention effect (EPR) coined by Matsumura and Maeda
(1986) (Figure 1). Many experimental tumours appear to selec-
tively concentrate macromolecules of around 20 kDa molecular
mass. This phenomenon is not due to just the leakiness of the
tumour vasculature but also lack of the organized lymphatic
drainage that usually occurs in normal tissues. One strategy that
seems to be clinically useful at present is the incorporation of cyto-
toxic moieties into copolymers of hydroxypropylmethylacryl-
amide (HPMA) (Duncan, 1992). One of these compounds, PK1, is
a copolymer with peptidyl side-chains terminating in DOX (Figure
2). The stable side-chain is thought to ensure that there is no extra-
cellular release of DOX so that normal tissue toxicity is reduced.
The polymer–drug conjugate was designed so that the intact
macromolecule is taken up into cells by pinocytosis and trans-
ferred to the lysosomal compartment where it is exposed to an
array of enzymes resulting in release of DOX. PK1 containing at
least four times the normal clinical dose of DOX was delivered to
patients in a phase I trial and two responses were seen (Connors
and Pinedo, 1997). This kind of targeting seems a worthwhile
strategy to pursue, but it is imperative that appropriate in vivo
tumour models are employed in order to ensure the correct mole-
cules are selected rapidly for clinical study. Preclinical studies with
PK1 indicated that, not only was it active against vascularized
solid tumours in mice, it was also active against L1210 leukaemia
when delivered by the intraperitoneal route (Duncan et al, 1992).
Recent studies in this laboratory have also demonstrated that
tumours in which the blood vessels are not leaky are no more
responsive to PK1 than to DOX. This study also demonstrated
activity against avascular murine colon cancer lung colonies
(Loadman et al, 1998) suggesting that, although there is impelling
evidence from numerous studies that EPR plays a major role in the
activity of PK1, the absence of such a phenomenon from
micrometastases would not preclude activity. Appropriate studies
are required to further investigate this interesting approach.
There is evidence emerging that the endothelium of solid
tumour vasculature itself may be a useful target for drug therapy. It
has been known since the 1930s that colchicine caused anti-
vascular effects in experimental tumours (Clearkin, 1937) and it is
now clear that some clinically useful tubulin interactive agents
possess a vascular component in their mechanism of action against
murine solid cancer models (Hill et al, 1993). However, these
effects are seen only at doses close to MTD; the therapeutic index
is extremely small so the ratio of sensitivity of tumour endothe-
lium to normal cells is also small. A number of stilbenes, the
combretastatins, has been isolated from the South African bush
willow, Combretum caffrum, and based on them a series of
synthetic analogues has been synthesized (Pettit et al, 1989, 1995).
Combretastatin A4 has been shown to bind to tubulin at the
colchicine-binding site (McGown and Fox, 1989) and cause
tumour blood flow reduction (Chaplin et al, 1996), and Dark et al
(1997) have demonstrated vascular shutdown with combretastatin
A4 phosphate prodrug in s.c. experimental tumours at less than
one-tenth of the MTD. Fearing the possibility of transplantation
artefacts in these anti-vascular effects we have examined the
efficacy of both combretastatin A4 and its prodrug on orthotopi-
cally transplanted murine colon tumours and ensuing metastatic
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Figure 3 Haemorrhagic necrosis in an orthotopically implanted colon
tumour and its metastasis following treatment with the investigational agent
combretastatin A4 (courtesy of K Grosios). (A) Control caecal implant;
(B) treated caecal implant; (C) treated metastatic deposit deposits (Grosios et al, 1997). Both parent compound and prodrug
caused major haemorrhagic necrosis in tumours at the orthotopic
site and in metastatic deposits (Figure 3). Careful examination of
morphological effects indicated that lung deposits that had not
undergone neovascularization did not respond to either compound,
indicating that vascularization and not transplantation site
seems to be the important component for the activity of these
compounds. The combretastatin A4 prodrug is awaiting phase I
clinical trial and it remains to be seen whether the vascular effects
predicted from the preclinical models will occur.
Another compound selected for clinical trial on the basis of
preclinical anti-vascular effects is 5,6-dimethyl xanthenone acetic
acid (XAA). This is a more potent analogue of flavone acetic acid
(FAA) (Atassi et al, 1985) from a series developed by Baguley and
colleagues in Auckland, New Zealand (Atwell et al, 1989;
Rewcastle et al, 1989, 1991a, 1991b, 1991c). FAA is an interesting
molecule that had impressive experimental activity but, disap-
pointingly, failed to show any clinical activity (reviewed by Bibby,
1991; Bibby and Double, 1993). XAA again showed impressive
haemorrhagic necrosis in vascularized solid tumour models but
this time at tenfold lower doses than FAA (Rewcastle et al, 1991a;
Ching et al, 1992; Laws et al, 1995a) and also caused widespread
haemorrhagic necrosis in an orthotopic model of human colon
cancer (Laws et al, 1995b). Phase I clinical trials are ongoing in
Auckland and in Mt Vernon Hospital/Gray Laboratory and
Bradford, UK. To date, tumour vascular effects have been noted in
two patients (Rustin et al, 1998) suggesting that the preclinical
models may well have been predictive in this case but, more
importantly, demonstrating proof of principle, i.e. that a vascular
effect demonstrated in in vivo preclinical models can also occur in
solid malignancies in man. These clinical effects suggest that this
anti-vascular strategy may well be worth pursuing with other more
potent chemical entities.
A particularly interesting development that again relies on thor-
ough characterization of in vivo models has come from the identi-
fication that certain peptides home specifically to the vasculature
of specific organs (Pasqualini and Ruoslahti, 1996) and to tumour
vasculature (Arap et al, 1998). In the latter study the authors have
demonstrated that it may be possible to target chemotherapeutic
drugs specifically to tumour vasculature on the basis of differential
expression of receptors.
ORTHOTOPIC TUMOUR MODELS
It is now clear from large numbers of studies, some of which are
cited here, that it is necessary to take account of not only the rele-
vance of the tumour type utilized for the in vivo evaluation of
novel drugs and other therapeutic strategies but also tumour site.
In order to do this it is necessary to use model systems that reflect
the morphology and growth characteristics of clinical disease but,
equally as importantly, must be technically feasible and ethically
acceptable to carry out. For the last 20 years good studies have
been reported in the literature indicating that such orthotopic
systems exist (e.g. Tan et al, 1977; Goldrosen et al, 1986; Bresalier
et al, 1987; Morikawa et al, 1988; Fu et al, 1991) and the worth of
such systems has been extensively reviewed (Fidler et al, 1990;
Fidler, 1991; Gutman and Fidler, 1995; Hoffman, 1997). It is
important to remember that, in the case of common solid cancers
in humans, the primary tumour mass is usually excised by the
surgeon and it is the metastases that require novel therapeutic
strategies, so models should reflect these clinical metastases. It is
still necessary to refine orthotopic techniques in order to improve
the predictability of these models in the future, either by character-
ization for specific molecular targets within these clinically rele-
vant sites of metastasis, or to develop similar models with tumour
cells appropriately transfected to express the target of interest. It
must be remembered that, if one adopts an orthotopic approach
with models for drug discovery, due attention is given to appro-
priate end-points. Lethality should not be seen as an alternative to
a specific pharmacodynamic end-point such as changes in blood
flow in the case of anti-vascular strategies or production of
cytokines by immunomodulators etc.
CONCLUSIONS
It is clear that murine tumour models have been very helpful in
determining basic principles of cancer chemotherapy and to date
have been instrumental in identifying and evaluating a limited
number of clinically useful agents. Contrary to popular belief
many murine tumours are not easy to cure with standard
chemotherapeutic agents and, if adequate attention is paid to clini-
cally relevant end-points and therapeutic index, they can be good
predictors of clinical activity. Of course today a whole host of
approaches and assays is available to drug-discovery teams:
• high throughput robotic cell-free screens
• in vitro cell lines (sometimes genetically modified to express a
specific target)
• hollow-fibre in vivo assays
• induced rodent tumour systems – usually intraperitoneal or
subcutaneous
• spontaneous rodent tumours
• models of metastasis
• orthotopic models
• human tumour xenografts
• transgenic systems.
Modern drug discovery should be much more mechanistically
based and target-driven, so the first two of these systems should
continue to lead to identification of structures that have potential
for development. Assays like the NCI hollow-fibre screen provide
a rapid and relatively inexpensive method for assessing in vivo
potential. The remaining systems should be carefully selected
based on the particular therapeutic approach. The evidence from
the literature is clear in that it indicates that rodent tumours should
not be used for random screening. It is necessary to fully charac-
terize tumour models to ensure that the precise target for the
strategy being evaluated is expressed in vivo. Since targets are
known to vary with different anatomical sites, more effort should
be placed on developing models in clinically relevant sites rather
than the continuous use of subcutaneously transplanted tumours
whilst ignoring their tissue of origin or likely site of metastasis in
humans. Ultimately, regardless of the molecule being investigated
and developed, it is necessary to produce a safe pharmaceutical
preparation that can be delivered in an appropriate way to reach
the target for which it has been designed, so to make real progress
in drug development appropriate in vivo rodent models are still
essential. However, in addition to scientific considerations, due
ethical consideration must be given to ensure selection of the
appropriate model for the task in hand and animal welfare guide-
lines must be followed throughout.
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does it make scientific sense, to use large panels of murine
tumours or human tumour xenografts for extensive in vivo
screening, particularly when these xenografts are often poorly
characterized. The most efficient and ethical approach must be
to design limited, but relevant, experiments to address key
questions, e.g:
• Can effective drug concentrations based on previous in vitro
data be achieved in vivo?
• Is the molecule reaching its designated clinically relevant
target?
• Is there efficacy or, in other words, is there proof of principle?
If these questions can be answered in the affirmative then the
compound should be scheduled for clinical trial without the need
for further extensive in vivo testing.
In summary, there are certain key requirements for in vivo
studies:
• Models must have known clinically-relevant target status.
• Appropriate bioavailability of test molecules should be demon-
strated.
• Consideration of therapeutic index is vital.
• The anatomical site of the tumour should be considered.
Proof of principle can be achieved with the use of individually
tailored rodent model systems, whether they be syngeneic murine
or human tumours, and these should continue to have a key role in
selecting those compounds for clinical evaluation that have the
best chance of causing a significant therapeutic benefit to the
patient. Hopefully the days of screening in large panels of poorly
characterized tumours in animals are a thing of the past.
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